[{"address1": "Ugland House", "address2": "PO Box 309", "city": "Grand Cayman", "zip": "KY1-1104", "country": "Cayman Islands", "phone": "848-230-7430", "website": "https://www.adlainortye.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.", "fullTimeEmployees": 123, "companyOfficers": [{"maxAge": 1, "name": "Mr. Yang  Lu", "age": 43, "title": "Co- Founder, CEO & Chairman", "yearBorn": 1981, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kaiyang  Tang", "age": 59, "title": "President", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Xiaofeng  Ye", "age": 45, "title": "Interim CFO and VP of Business Development & Commercialization Strategy", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ngai Chiu  Tse M.D., Ph.D.", "age": 57, "title": "Head of Research & Development", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.6, "open": 1.62, "dayLow": 1.62, "dayHigh": 1.686, "regularMarketPreviousClose": 1.6, "regularMarketOpen": 1.62, "regularMarketDayLow": 1.62, "regularMarketDayHigh": 1.686, "payoutRatio": 0.0, "forwardPE": -1.0055555, "volume": 2141, "regularMarketVolume": 2141, "averageVolume": 15549, "averageVolume10days": 12720, "averageDailyVolume10Day": 12720, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 60110588, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 4.1, "priceToSalesTrailing12Months": 30.984838, "fiftyDayAverage": 1.8579, "twoHundredDayAverage": 2.13746, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 143188288, "profitMargins": 0.0, "floatShares": 59847067, "sharesOutstanding": 31236900, "sharesShort": 7203, "sharesShortPriorMonth": 2977, "sharesShortPreviousMonthDate": 1745971200, "dateShortInterest": 1748563200, "sharesPercentSharesOut": 0.0002, "heldPercentInsiders": 0.1425, "heldPercentInstitutions": 0.0018099999, "shortRatio": 0.77, "shortPercentOfFloat": 0.0002, "impliedSharesOutstanding": 36900300, "bookValue": 0.691, "priceToBook": 2.3574529, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -51869000, "trailingEps": -1.62, "forwardEps": -1.62, "enterpriseToRevenue": 73.808, "enterpriseToEbitda": -2.758, "52WeekChange": -0.50636363, "SandP52WeekChange": 0.09203708, "quoteType": "EQUITY", "currentPrice": 1.629, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 61159000, "totalCashPerShare": 0.552, "ebitda": -51924000, "totalDebt": 27226000, "quickRatio": 1.349, "currentRatio": 1.412, "totalRevenue": 1940000, "debtToEquity": 106.831, "revenuePerShare": 0.061, "returnOnAssets": -0.32840002, "returnOnEquity": -1.0319, "grossProfits": 1940000, "freeCashflow": -30614000, "operatingCashflow": -51819000, "revenueGrowth": 1.18, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -12.208759, "financialCurrency": "USD", "symbol": "ANL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 1.8124952, "regularMarketPrice": 1.629, "shortName": "Adlai Nortye Ltd.", "longName": "Adlai Nortye Ltd.", "marketState": "CLOSED", "ipoExpectedDate": "2023-09-29", "averageAnalystRating": "3.0 - Hold", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1695994200000, "regularMarketChange": 0.028999925, "regularMarketDayRange": "1.62 - 1.686", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 15549, "fiftyTwoWeekLowChange": 0.5289999, "fiftyTwoWeekLowChangePercent": 0.48090902, "fiftyTwoWeekRange": "1.1 - 4.1", "fiftyTwoWeekHighChange": -2.471, "fiftyTwoWeekHighChangePercent": -0.60268295, "fiftyTwoWeekChangePercent": -50.636364, "earningsTimestamp": 1746043200, "earningsTimestampStart": 1754650740, "earningsTimestampEnd": 1755864000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.62, "epsForward": -1.62, "epsCurrentYear": -0.36, "priceEpsCurrentYear": -4.5249996, "fiftyDayAverageChange": -0.22890007, "fiftyDayAverageChangePercent": -0.12320366, "twoHundredDayAverageChange": -0.50846004, "twoHundredDayAverageChangePercent": -0.2378805, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "exchange": "NGM", "messageBoardId": "finmb_1830112145", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketTime": 1749844800, "displayName": "Adlai Nortye", "trailingPegRatio": null, "__fetch_time": "2025-06-14"}]